Clinical trial
Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When…
NCT00307034 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00307034 |
|---|---|
| Title | Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule |
| Official title | An Open, Randomized, Phase IIIa Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Administered Intramuscularly According to a 2-4-11 Months Vaccination Schedule |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Streptococcal |
| Intervention type | Biological |
| Interventions | GSK Biologicals' 10-valent pneumococcal conjugate vaccine., Infanrix hexa., Infanrix-IPV/Hib. |
| Enrollment | 351 |
| Start date | Jan 1, 2006 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 25, 2007 |
| First posted | Mar 27, 2006 |
| Last update posted | Jun 8, 2018 |
| Countries | Denmark, Norway, Slovakia, Sweden |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: